| Dr Ryan Livengood, MD | |
|
327 Medical Park Dr, Bridgeport, WV 26330-9006 | |
| (681) 342-1523 | |
| (681) 342-1548 |
| Full Name | Dr Ryan Livengood |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 20 Years |
| Location | 327 Medical Park Dr, Bridgeport, West Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073710802 | NPI | - | NPPES |
| 3810014842 | Other | WV | MEDICAID |
| WV3496A | Other | WV | MEDICARE PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZH0000X | Pathology - Hematology | 22497 (West Virginia) | Secondary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 22497 (West Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Berkeley Medical Center | Martinsburg, WV | Hospital |
| Jefferson Medical Center | Ranson, WV | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| West Virginia University Medical Corporation | 1052224565 | 1613 |
News Archive
Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.
Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
The Southwest Oncology Group, the largest of several National Cancer Institute-sponsored clinical trials networks, has permanently closed enrollment in a trial comparing a standard drug therapy, dexamethasone, with a combined therapy of the same drug plus the drug lenalidomide (Revlimid) for people newly diagnosed with multiple myeloma.
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma.
› Verified 9 days ago
| Entity Name | West Virginia University Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275504508 PECOS PAC ID: 1052224565 Enrollment ID: O20031111000207 |
News Archive
Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.
Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
The Southwest Oncology Group, the largest of several National Cancer Institute-sponsored clinical trials networks, has permanently closed enrollment in a trial comparing a standard drug therapy, dexamethasone, with a combined therapy of the same drug plus the drug lenalidomide (Revlimid) for people newly diagnosed with multiple myeloma.
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma.
› Verified 9 days ago
| Entity Name | University Healthcare Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659625739 PECOS PAC ID: 8325291404 Enrollment ID: O20130124000127 |
News Archive
Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.
Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
The Southwest Oncology Group, the largest of several National Cancer Institute-sponsored clinical trials networks, has permanently closed enrollment in a trial comparing a standard drug therapy, dexamethasone, with a combined therapy of the same drug plus the drug lenalidomide (Revlimid) for people newly diagnosed with multiple myeloma.
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ryan Livengood, MD 327 Medical Park Dr, Bridgeport, WV 26330-9006 Ph: (681) 342-1523 | Dr Ryan Livengood, MD 327 Medical Park Dr, Bridgeport, WV 26330-9006 Ph: (681) 342-1523 |
News Archive
Janssen Research & Development, LLC (Janssen), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of canagliflozin, an investigational, oral, once-daily, selective sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with type 2 diabetes.
Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
The Southwest Oncology Group, the largest of several National Cancer Institute-sponsored clinical trials networks, has permanently closed enrollment in a trial comparing a standard drug therapy, dexamethasone, with a combined therapy of the same drug plus the drug lenalidomide (Revlimid) for people newly diagnosed with multiple myeloma.
Mount Sinai researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for never-before-defined subtypes of a blood cancer called multiple myeloma.
› Verified 9 days ago
Gerald Wedemeyer, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 327 Medical Park Drive, Bridgeport, WV 26330 Phone: 681-342-1525 Fax: 681-342-3125 | |
Dr. Brock Joseph Oliverio, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 327 Medical Park Dr, Bridgeport, WV 26330 Phone: 681-342-1610 Fax: 681-342-1626 | |
Matthew Scott Szarko, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 327 Medical Park Dr, Bridgeport, WV 26330 Phone: 681-342-1000 |